MeiraGTx Limited

About MeiraGTx Limited

MeiraGTx Limited is a pioneering gene therapy company based in the UK, dedicated to transforming the treatment landscape for patients with serious diseases. Our mission is to develop innovative therapies that harness the power of gene editing and delivery technologies to address unmet medical needs.

At MeiraGTx, we focus on developing treatments for a range of genetic disorders, including inherited retinal diseases and neurodegenerative conditions. Our proprietary platform enables us to create targeted gene therapies that can potentially restore normal function at the genetic level.

We are committed to advancing our research through rigorous clinical trials, ensuring that our therapies are both safe and effective. Our team comprises leading scientists and industry experts who are passionate about making a difference in patients’ lives.

In addition to our core research activities, we actively collaborate with academic institutions and industry partners to accelerate the development of our therapies. We believe that collaboration is key to driving innovation and achieving our goals.

As we look to the future, MeiraGTx Limited aims to expand our pipeline of gene therapies and bring new hope to patients worldwide. We are driven by our vision of a world where genetic diseases can be effectively treated, allowing individuals to lead healthier, more fulfilling lives.

• Core Activities: Gene therapy development, clinical trials, collaborations with academic and industry partners.
• Vision: To transform the treatment of genetic diseases through innovative therapies.